new glp 1 agonist Comparing Ozempic, Wegovy and Other GLP-1 Drugs Beyond GLP-1: New 5-In-1 Compound

Dejgaard TF, Schmidt S, Frandsen CS et al (2020) Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump triala randomized, double-blinded, placebo-controlled trial

If you've reached a plateau on adequate GLP-1 therapy, discuss alternatives with your prescriber rather than adding phentermine without clear clinical justification

Effects of tirzepatide versus insulin glargine on cystatin c-based kidney function: a SURPASS-4 post hoc analysis

Let us know

Issue Section License Copyright (c) 2025 Canadian Diabetes & Endocrinology Today This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License